Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 15/20 | 0.66 |
| ▸ | HTR1B | P28222 | 6/20 | 0.66 |
| ▸ | HTR1D | P28221 | 5/20 | 0.66 |
| ▸ | HTR1A | P08908 | 2/20 | 0.65 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | DRD1 | P21728 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | HTR1F | P30939 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754352 | 1.00 | HTR6 (0.66) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| SCHEMBL8789709 | 0.90 | HTR1B (0.70) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| SCHEMBL8506717 | 0.80 | HTR1B (1.00) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| SCHEMBL8506720 | 0.80 | HTR1B (1.00) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| SCHEMBL1697466 | 0.80 | HTR1B (0.67) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| SCHEMBL8984139 | 0.80 | HTR1B (0.75) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| SCHEMBL5647758 | 0.80 | HTR6 (0.66) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| Bromide SCHEMBL505857 | 0.79 | HTR6 (0.65) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| Eletriptan SCHEMBL798473 | 0.79 | HTR1B (1.00) | HTR6HTR1BHTR1DHTR1ACHRM2 | |
| Eletriptan SCHEMBL1556539 | 0.79 | HTR1B (1.00) | HTR6HTR1BHTR1DHTR1ACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5807571-A | Transdermal therapeutic systems for administering indole serotonin agonists | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1998-09-15 | — | — | US | claimed |
| US-8609134-B2 | Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same | TEIKOKU PHARMA USA, INC. (US) | 2013-12-17 | — | — | US | disclosed |
| US-20110002967-A1 | Methods of Transdermally Administering an Indole Serotonin Receptor Agonist and Transdermal Compositions for Use in the Same | TEIKOKU PHARMA USA, INC. | 2011-01-06 | — | — | US | disclosed |
| US-7816394-B2 | Methods of transdermally administering an indole serotonin receptor agonist and transdermal compositions for use in the same | TEIKOKU PHARMA USA INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2170063-A1 | ORGANOLEPTICALLY ACCEPTABLE INDOLE SEROTONIN RECEPTOR AGONIST ORAL DOSAGE FORMULATIONS AND METHODS OF USING THE SAME | Teikoku Pharma USA, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2009014960-A1 | ORGANOLEPTICALLY ACCEPTABLE INDOLE SEROTONIN RECEPTOR AGONIST ORAL DOSAGE FORMULATIONS AND METHODS OF USING THE SAME | TEIKOKU PHARMA USA, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| US-20090028802-A1 | ORGANOLEPTICALLY ACCEPTABLE INDOLE SEROTONIN RECEPTOR AGONIST ORAL DOSAGE FORMULATIONS AND METHODS OF USING THE SAME | TEIKOKU PHARMA USA, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20070140977-A1 | METHODS OF TRANSDERMALLY ADMINISTERING AN INDOLE SEROTONIN RECEPTOR AGONIST AND TRANSDERMAL COMPOSITIONS FOR USE IN THE SAME | TEIKOKU PHARMA USA, INC. | 2007-06-21 | — | — | US | disclosed |
| US-5807571-A | Transdermal therapeutic systems for administering indole serotonin agonists | LTS LOHMANN THERAPIE-SYSTEME GMBH (DE) | 1998-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070140977-A1 | METHODS OF TRANSDERMALLY ADMINISTERING AN INDOLE SEROTONIN RECEPTOR AGONIST AND TRANSDERMAL COMPOSITIONS FOR USE IN THE SAME | HTR7, TPH1, TPH2 | HTR6 12/4885HTR1B 14/4885HTR1D 25/4885 |
| US-20110002967-A1 | Methods of Transdermally Administering an Indole Serotonin Receptor Agonist and Transdermal Compositions for Use in the Same | HTR7, TPH1, TPH2 | HTR6 12/4885HTR1B 14/4885HTR1D 25/4885 |
| US-20090028802-A1 | ORGANOLEPTICALLY ACCEPTABLE INDOLE SEROTONIN RECEPTOR AGONIST ORAL DOSAGE FORMULATIONS AND METHODS OF USING THE SAME | HTR5A, HTR3A, HTR1A | HTR6 9/4885HTR1B 20/4885HTR1D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.